Search research articles
Contact Us
Filters
Showing results (41-50 of 122) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
Antonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Bone Marrow Transplantation
|
October 4, 2024
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor
Giuseppe Bertuglia, Bruno Garibaldi, Andrea Casson, et al.
Haematologica
|
February 29, 2020
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, et al.
Blood
|
May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Blood
|
August 29, 2012
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination
Giulia Benevolo, Alessandra Stacchini, Michele Spina, et al.
Haematologica
|
March 24, 2018
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
Daniela Drandi, Elisa Genuardi, Irene Dogliotti, et al.
American Journal of Hematology
|
October 5, 2016
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
Nicola Polverelli, Massimo Breccia, Giulia Benevolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Blood
|
March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma
Alessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Leukemia & Lymphoma
|
February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
Alessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 122) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
Antonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Bone Marrow Transplantation
|
October 4, 2024
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor
Giuseppe Bertuglia, Bruno Garibaldi, Andrea Casson, et al.
Haematologica
|
February 29, 2020
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, et al.
Blood
|
May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Blood
|
August 29, 2012
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination
Giulia Benevolo, Alessandra Stacchini, Michele Spina, et al.
Haematologica
|
March 24, 2018
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
Daniela Drandi, Elisa Genuardi, Irene Dogliotti, et al.
American Journal of Hematology
|
October 5, 2016
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
Nicola Polverelli, Massimo Breccia, Giulia Benevolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Blood
|
March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma
Alessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Leukemia & Lymphoma
|
February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
Alessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Page
of 13